RxSight has faced class-action securities lawsuits filed by disgruntled investors alleging that the company and certain executives issued misleading statements or failed to disclose timely information regarding adoption hurdles and slower-than-expected utilization rates for its light delivery systems. The complaints focus on significant downward revisions to full-year financial revenue guidance that triggered sharp stock price drops, prompting legal firms to investigate potential violations of federal securities laws and assess recovery options for affected shareholders who purchased securities during specific class periods.